Chronix news Events Videos Testimonials
Dr hab. n. med. Jakub Dobruch, FEBU. Urological Review, The Polish Association of Urology bimonthly magazine. No. 5/2016
Liquid Biopsy is an example of a new kind of research that could revolutionize cancer detection and treatment of patients affected.
Prof. Piotr Radziszewski. New generation oncological biomarkers – focusing on Chronix company. 1.10.2016.
We present a lecture delivered at the 5th Polish women and men health debate according to Medical guidelines – kidney cancer, bladder cancer.
Beck J, Urnovitz HB, Mitchell WM, Schütz E. Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls. Mol Cancer Res 2010; 8:335-42.
Chronix has first used the NGS technology for investigation into the use in breast cancer with very promising results.
Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, et al. Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer. Clin Chem 2015;61:239-48.
In order to discriminate between normal interindividual variabilities and traces from cancer, the situation in healthy individuals is of critical knowledge.
Weiss, G. et al. Tumor cell-free DNA copy number instability (CNI) to predict therapeutic response to immunotherapy prior to cycle 2. J ClinOncol 34, 2016 (suppl; abstr 3027).
We measured CNAs changes during treatment by computing a genomic copy number instability index (CNI) of cfDNA and Treg-specific demethylation region (TSDR) as measure for Tregs% of leukocytes compared to response.
Weiss, Glen J., et al. Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers. Cancer Research 76.14 Supplement (2016): 3138-3138.
Gains and losses of chromosomal regions – as a hallmark of cancer – have been detected in plasma as copy number aberrations (CNAs), and for several cancers a relation to tumor size has been reported.